Canton Strategic Holdings, Inc. is a US-based company involved in institutional blockchain adoption and the digitization of financial markets. It operates in two segments: Digital Asset Treasury and Clinical Stage Biotechnology. The Digital Asset Treasury segment covers Canton Coin-centric treasury strategies, including validator operations, network participation, application support, strategic investments, ecosystem collaboration, capital raising, treasury expansion, token management (locking, lending, and options), the Canton Foundation, and governance and risk management. The biotechnology segment researches and develops GV104, a buccal film formulation of nalmefene for respiratory depression and prophylactic protection against synthetic opioid exposure in military and first responders, and GV023, an oral anti-tumor necrosis factor-alpha monoclonal antibody addressing limitations of repeated intravenous infusions. Formerly known as Tharimmune, Inc., the company changed its name to Canton Strategic Holdings, Inc. in February 2026. It was incorporated in 2017 and is headquartered in Red Bank, New Jersey.
USA